<SEC-DOCUMENT>0001193125-13-151027.txt : 20130411
<SEC-HEADER>0001193125-13-151027.hdr.sgml : 20130411
<ACCEPTANCE-DATETIME>20130411161225
ACCESSION NUMBER:		0001193125-13-151027
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130408
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130411
DATE AS OF CHANGE:		20130411

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS INC
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		13756401

	BUSINESS ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-489-2100

	MAIL ADDRESS:	
		STREET 1:		810 SEVENTH AVENUE
		STREET 2:		FL 35
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d519787d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of report (Date of earliest event reported): April&nbsp;11, 2013 (April 8, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>DELCATH SYSTEMS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-16133</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1245881</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>810 Seventh Avenue, 35<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, New York, New York, 10019 </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212)
489-2100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NONE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02(e) Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. (the &#147;Company&#148;) announced that Jennifer Simpson, PhD, M.S.N., C.R.N.P., has been appointed to the newly created
position of Executive Vice President, Global Head of Business Operations. Dr.&nbsp;Simpson joined the Company in March 2012 as the Company&#146;s Executive Vice President, Global Marketing. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Executive Vice President, Global Sales, Agustin Gago, has left the employment of the Company, effective April&nbsp;8, 2013. It is
anticipated that Mr. Gago will receive certain severance payments, and will continue to serve as a consultant to the Company. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;8, 2013, the Company issued a press release announcing Dr.&nbsp;Simpson&#146;s promotion to Executive Vice President, Global Head of
Business Operations and the elimination of the positions of Executive Vice President, Global Sales and Executive Vice President, Business Development, a copy of which release is filed as Exhibit 99.1 to this Form 8-K and which is incorporated by
reference herein. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
following exhibit is filed herewith: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated April 8, 2013</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">DELCATH SYSTEMS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: April&nbsp;11, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Peter J. Graham</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peter J. Graham</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executive Vice President, General Counsel</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of Delcath Systems, Inc., dated April 8, 2013</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d519787dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g519787g46u30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>DELCATH EXPANDS PROGRAM TO INCREASE EFFICIENCIES AND REDUCE&nbsp;CASH&nbsp;UTILIZATION
</B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Jennifer Simpson, PhD, MSN, CRNP Named Executive Vice President, Global&nbsp;Head&nbsp;of&nbsp;Business&nbsp;Operations
</I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEW YORK, NY &#150; April&nbsp;8, 2013</B> &#150; Delcath Systems, Inc. (NASDAQ: DCTH) today announced that as a
part of the Company&#146;s continued effort to increase efficiencies and reduce cash utilization, it has implemented a program designed to decrease the Company&#146;s 2013 quarterly operating cash utilization to between $9 million and $10 million
from the previously communicated range of $9 million to $12 million, beginning in the second half of 2013. Combined with the Company&#146;s approximate $42 million cash position at March&nbsp;31, 2013, the program is expected to provide Delcath with
sufficient resources for at least the next 12 months as the Company pursues three key objectives: U.S. FDA approval for Melblez</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System), European commercialization
of CHEMOSAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Hepatic Delivery System for melphalan hydrochloride, and ongoing clinical development focused on
label expansion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">To achieve the program&#146;s goals, Delcath has expanded workforce restructuring actions which have reduced the
Company&#146;s workforce by approximately 21 percent this year. In addition, the actions announced today are expected to continue the Company&#146;s reduction of expenses incurred with outside consultants. To increase efficiency, the Company will be
changing the address of its headquarters to its Queensbury, NY facilities, and is pursuing a relocation project to move its New York City operations to a more cost effective satellite office in New Jersey. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expanded efficiency program includes the promotion of Jennifer Simpson, Ph.D., MSN, CRNP to the newly created position of Executive Vice President,
Global Head of Business Operations, effective immediately. Dr.&nbsp;Simpson joined Delcath in March 2012 as Executive Vice President, Global Marketing, bringing an extensive background in pharmaceutical and oncology marketing, including
responsibility for global product development in the oncology sector. In her new capacity, Dr.&nbsp;Simpson will have responsibility for global sales, marketing, regulatory, quality, clinical development, and medical affairs activities. The
efficiency program includes the elimination of two senior level positions; global sales, the responsibilities of which have been absorbed by Dr.&nbsp;Simpson and business development, the responsibilities of which have been absorbed by
Delcath&#146;s President&nbsp;&amp; CEO, Eamonn Hobbs, and CFO, Graham&nbsp;Miao. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The expansion of these programs
will significantly increase our organizational efficiencies, reduce expected cash burn in 2013, and provide the necessary resources to fund our three key strategic priorities,&#148; said Mr.&nbsp;Hobbs. &#147;Our team is highly focused on
preparations for our May&nbsp;2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Oncologic Drugs Advisory
Committee panel meeting, as well as our ongoing dialogue with the FDA regarding their review of our NDA submission.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>About Delcath Systems </U></I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary drug/device
combination product, the Delcath Hepatic Delivery System, is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The
Company&#146;s initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase 3 clinical trial for patients with metastatic melanoma in the liver had successfully achieved the
study&#146;s primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase&nbsp;2 trial to treat other liver cancers. Outside of the United States, our proprietary product to deliver and filter
melphalan hydrochloride is marketed under the trade name Delcath Hepatic CHEMOSAT<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Delivery System (CHEMOSAT
Delivery System for Melphalan.) The Company obtained authorization to affix a CE&nbsp;Mark for the Generation Two CHEMOSAT Delivery System for Melphalan in April 2012. The right to affix the CE&nbsp;mark allows the Company to market and sell the
CHEMOSAT Delivery System for Melphalan in Europe. In October 2012, the Company satisfied all of the requirements to affix the CE&nbsp;Mark to the Hepatic CHEMOSAT Delivery System device for intra-hepatic arterial delivery and extracorporeal
filtration of doxorubicin hydrochloride injection (CHEMOSAT Delivery System for Doxorubicin), providing a regulatory pathway for the CHEMOSAT Delivery System for Doxorubicin for countries in Asia that accept the CE&nbsp;Marking as part of their
national regulatory requirements. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company&#146;s NDA has been accepted for filing and substantive review by the FDA. For more information,
please visit the Company&#146;s website at www.delcath.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Private Securities Litigation Reform Act of 1995 provides a safe harbor for
forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.
Factors that may cause such differences include, but are not limited to, uncertainties relating to: the outcome of the ODAC meeting, and the impact, if any, of the advisory panel&#146;s recommendation on the FDA&#146;s decision regarding the
Company&#146;s new drug application (NDA), timing of completion of the FDA&#146;s review of our NDA, the extent to which the FDA may request additional information or data and our ability to provide the same in a timely manner, acceptability of the
Phase 1, 2 and 3 clinical trial data by the FDA, FDA approval of the Company&#146;s NDA for the treatment of ocular metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, adoption, use and resulting sales,
if&nbsp;any, for the CHEMOSAT system to deliver and filter melphalan in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with primary and
metastatic disease in the liver, market acceptance of the Gen Two CHEMOSAT system and patient outcomes using the same, approval of the current or future chemosaturation system for delivery and filtration of melphalan, doxorubicin or other
chemotherapeutic agents for various indications in the US </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, our ability to successfully enter into strategic partnership and distribution arrangements in foreign markets
including Australia and key Asian markets and timing an revenue, if any, of the same, the approval of the Hepatic CHEMOSAT Delivery System device to deliver and filter doxorubicin in key Asian markets and patient outcomes using the same, our ability
to obtain reimbursement for the CHEMOSAT system, uncertainties relating to the timing and results of research and development projects, uncertainties relating to the timing and results of future clinical trials, and uncertainties regarding our
ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not
place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they
are&nbsp;made. </I></FONT></P> <P STYLE="margin-top:48px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">#&nbsp;#&nbsp;# </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g519787g46u30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g519787g46u30.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````+P4*!!1`0`!`````4)@@A%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E``"@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`$P`^`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/>W;`8YZ5X[-\<YH;F:+^P4/ENR
M9^TXS@X_NU[%)_JW/HIKX_O&)N[IAU,CD?\`?1KIPM.,V^8YZ\Y0M8];_P"%
M[3_]"^G_`(%'_P")JWI_QSM9)E74='F@C)YDBDW[?J,"M'0_A5X6OM`T^YN+
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M,QD$^_H0,8P/6L/X[/\`Z/HD???*WZ+63\#XR?$NI2'HMJ!GZM_]:M52C[#G
MZF;J2]KR]#W<49KS[QS\3+;PI.+"TA%WJ)&60MA(P>1N/OZ5YVWQJ\4>86$6
MGJO93$W_`,564,/4FKHTE6C%V/H6BN&^&_C.\\8Z?>RWL$,4MM(J`Q$X8$9S
MS7/>+_BS?:)XBNM'T[389FMV"M)(S'<2,\`?7UJ?93YG'L/VD>7F/6`3[TO;
MK7@4_P`7/&5NP::QMH%8_*)+9P#[#GFNT\!?$]O%6H'3+^T2WNRI>-XB=C@=
M1ST-5/#3C'F%&M%NVQWU_J-GIEL;B^NXK>'./,D<*,_6L?2_'.@ZUK']EZ;?
M?:;G8SG8C;0![XQWKR#XG^-+W5K^_P##DMO;K:6EUE9%)WMMZ9[=ZY7POXGN
M?">KMJ5I!#-*8S%LE)Q@_3Z5K#"-PYNIG*O:5NA]*^)=9/A[PY>:L(O.-LF_
MRRV-W('7\:\ZT?XT3ZIK%CIXT-4-S,D6_P"TYVY."<;><5>UCQ#<>(/@C>ZM
M>0Q)-.F"D9.W`D`&,UXWX;OX-*\2V%_=,1#:R[V*CDX!P!^-50HQE"7,M4%6
MHU)-'UG2UX#>_&SQ!-<NUE:64$`)VK(K.V/<Y%=)X(^+<^M:S!I6LVT,4MP=
ML4T.0"WH02>M82PU1*]C15H-V/6J*2EK$U"BHI9XH%W2R*@]S5(ZW8!L&X4>
M^*+-["N:5%0PSQ3J&BD5U]C4U+5;C"BBBF`4444`5[M@EI.W]U&/Z5\?R-O9
MV_O$_K7UOKLOV;0-2GSC9;R-GZ*:^1@05!S[BN[`K<Y,3T/KG1$\O0-.3'2U
MB'_CHKR'XXW\$E]I6G(098E>60#G:#P!_6L4?&/Q(EDEM!%8Q!$"*XC9B`!C
MUQGZUQLDNI^(=6:4B>^O[ALD*-Q8_P"'Z"G1P\H3YY,52LI1Y8G9?!V*1_'+
M3X)6"UD+D>AZ5Q^O7\NJZ]J-[,Q,DL[GGL`<`?D*][^&G@IO"ND22WH4ZA=X
M,H'/EJ.B?XUXIXT\.7'ASQ)>6T\;?9Y9&D@EP=KJ3G`/J*NG4C.LV3.#C31T
MNF^.=0T[PTFBP^$D>T,)B+&)R9,C[QXYKBK73]2CN[>1+"\#)*A4^2W!!'M7
MH'AWXQW&E:5#8ZAIHNS`FQ)D?:2!TR,&NE\)?$R_\7>+8=-BTRWMK3RVDD)<
MN^!CV'<T<TJ=WR:`E&5ES&)\<)B;K0HC]X0NY_'`IWP*3-[K4G=8XES^+53^
M.,ZMXGTZ+/,=H2?Q8UJ_`E!Y.MOG^.-?T;_&I>F&*WK'E.NWLE_KVHWDK$R2
MW#L?S(%>\^#?A]X?M?#EE+=:?!>75Q"LLDLR[N6&<#/0<UXUXY\/7/AWQ/>0
M31,MO-*TEO(1\KHQSU]1WK<T'XMZWH>E1:>UK;W:0J%B>3*L%'0$U=6,ZE->
MS9%-J,WSGN&EZ#H_AU;J73[:.SCE(>;:<+\N>>>G>O.]3^*7A;2+^X?1M(2]
MN9')DN0JHKMZ[\$FK4.L:YXS^$NM7Q2,7,I=88K<$91<9'KD\UXIILMG#J=K
M)?P--9K*#/$IP64=1[5C0H\SDYO5&E2I:RCLSI/%WQ`U+QC;QV\]K!;VD3[P
MD8))(Z9;^E6OA)'YOQ%LSCA(96/Y5+XW\::'K6C0:1H.E&SMDE$KNR*F<#&,
M#K^=2_!A0WCPMUVVDG]*W>E!Z6,TKU%=W-WXV:=I]E#ILUM:00W-Q/(TLB(`
MTG`ZGO6'\(-)L=6\1WL>H6D-U$EJ"$F0,`2W7!KH/CK%*%T:XP3`ID5FQP&.
M,5YWX2\6W7@[4I+VUBBF$L7ENLA(&,YR,5--.5"R*G:-74]I^)MM:Z7\,;RU
MLX(H(-R*L<:@*/F!X%>$:%I3ZWK]EI:,5-Q*(RP[+U)_(&O6_'^L7.J?!^PO
M;Z..*XO9HG,:G@9R0!GV%<)\*XQ-\1=,R!\@D?\`\</^-*@W"E)A5M*HCO/'
M7P[\/Z1X'N;RPMC%=685A-N)+Y(!S^=>7>#5+^-=$0<9O(S^1KWCXJRB'X=:
MF,@;]B_^/"O#O`*A_'VB#(XN0WY"GAY2=&3;"JDII(^I.G%5-0ODL;8R,-S'
MA5!ZFH4UFS?6&TL.WVI5W$;>/7K6/?E]4UH6R-B-#M!]!W->?%7>IV7((X+W
M6IV<MD`\L?NK]!5\>&6V<76&_P!SBK-_?Q:3`EM;(IDQP/0>IK&_M;4B?-$K
M[<]=GRU?O/;1$Z(62WO=%F$BG:"?O+]UOK72Z=?I?P!QPXX=?0U2L-1CU:%[
M:Y0"3;R/4>HK.LR^DZUY+G$9.T^X/0TFN;1C]#JZ*04M9E!1110!!<Q07$$E
MO<!'BD4JZ-T8'J#6`/!'A';C^Q+#I_<%:US'*TY*VR2#'WBV*B\B?_GRC_[[
MJHMK9B:3,_\`X0GPE_T!+#_O@5J6&EZ5I2%+"SM;8'KY2!<_E3/(F_Y\D_[[
MH\B?_GRC_P"^Z;;?47*NQH;T[,OYU5OK'3]2MVM[ZWM[B(]4E4,/UJ#R)_\`
MGRC_`.^J/(G_`.?&/_ONI2ML,PW^&O@R1]QTB#/7`D8#^=:FD>&-!T"5I=,T
M^WMI6&TR+]XCTR:L^1/_`,^4?_?=)]GFZ?8H_P#ONJ<F^HN5$6I>'-"U>X6Y
MU'3[6YF"[`\J@G'I4VEZ-I.B+(NF6=O:K(<N(AC=2?9Y_P#GR3_ONCR)O^?*
M/_OJC6UKCLB74=.TW5K8VU_;V]Q">=L@!P?:N=_X5IX+W[O['@^GF-C^=;OD
M3_\`/G'_`-]T>1/_`,^4?_?=";6S%RID^GV-AI=BEI8PPP6Z<JD>`HK$OO`?
MA+5+EKBYTFV:9B2S(2F3[X-:GD3?\^<?_?5!@G/6RC_[[%"=NH61F0^!/"4%
MOY2:+9>7G)++N/YGFKVF^&]"TBX-SI^G6MM,1M+QK@X]*E\B?/\`QY1_]]BC
MR)_^?*/_`+[%-R;W8**6R)]0L-/U6T:UOH(+B!NJ2`$9KG%^&O@M'WC1[<^Q
MD8C\LUN>3/\`\^2?]]T>1/\`\^2?]]TDW'9CLF)>:)HU]8PV-W9V\MK#@QQ.
M,JN!@8_"H+#POX>TR[6ZL-,M+>X4862-0"`:L^1/_P`^4?\`WW2>1/\`\^4?
M_?=*[VN*R)M1LM/U6S:VOX8;BW)RT<G()'M7/P:3X4TV^2XM=&A2>(Y2:*'E
M3[5M&"8#/V*/C_:K-DU:WAD*2VNQP<8(-./8&D:J1V#.^HQ1Q^=M.9,?-TK+
M\/J#/<7,H`8=,^YR:MQ,TT!F6Q41@9^8X-1VER+U':"T0A?O`G%"5DP*5I"-
M3U>66?\`U8.XJW&?05L'4[$7/V3/4[?N_*?:J=K=I>.T<%JA9>2&./:J=\3<
MW45M':E)5?DX]ZK=Z@&H0?V7JL4L/RHQW`#MZBK'B-`KVURO?(_J*/$I!-M'
MU<9)_E3O$'RZ?:*3AO\`ZU"Z`;"74:VJ2NZ@;0355=<M3)L(E'.-Q7BJZ++%
M:)(;)7`4'*G)_*J:ZQ;._EK:DOG&W:<U/*M1W.D$J,`0ZX/O16:L,S*"+)!G
MMNHJ;(";6+UM.TB]O4B,SP0M((QU;`S5'0I=7O+>"_N=0L;BVN(@ZI;PE=I/
M/#%CD?@*U+RZBLK66YGW>5&,MM4L<?05R.BSVT?BOR/#[O)I-Q$\MW$$(B@E
MX*E,]"V3E1^E(9UEW?VUBT`N91'Y\HACW=W/0427]O#?6]D\H%S.K-''W(7J
M:I>)=.?5-`N;>([;A0)87[K(IW*?S%9?A69O$$TWB:6(QK-&+>U1^J(/OG\7
MR/\`@-`&]J.J6NEP+-=RE$9@B;5+,['H%4<D_2I;2\BOK=9XO,"-G'F1E&_(
M@&L;Q2FG2V<*W]V]G(LOF6UT@YBD'0^GX'@U9\,ZA>:GH-O=WT7EW#9#?*5W
M@'`;:>1D#./>@")_%%E%XD?17$PG2)7W+$[+\QP!D#`^M;,LR0Q-)(X1%!9F
M8\`>IKF4NXK3XB72W.8S<64,<!*G#D,Q(!Z9JYXRL[B_\)ZA;6J.\K(#L3[S
MJ&!8#W(!'XT`3VGB33;V>*&&=PTP)B,D3QB4#^Z6`#?A6A>7EOI]E->74@B@
MA0O([=%`ZFN1TV+1-4O-/*:KJ5Q-`PGBMYF(\M@N/F&T8X)%;'C-&D\':I&J
M,YDA*;5&20<"@!J^,=#,FTWV-REHV:-@LH']PD8<^PSUJ]INMV.K^<MG,QD@
M;;)&Z%'3TR&`/-9&K6<9UWPI`+<-#!-(PPG";86"_2K&F(3XQUZ78RCR[=`2
M,!L!CQZ]:`-'4=6M-)6$W<C`RMLC1$9W=L9P%`)/K5FUNH[JWCFCW['&1O4J
M?R/-8'BLV&RVDGOVL;V`M+9W`0MAP,$8[@@X*]\U9T[7E.CZ7<:HIM+J_(C6
M$J>7/8#J`<9YZ"@#>H/2BB@#%U?5IM/U#1[>)487MUY,F[.0NTG(_*M6YGCM
M;66XF;9%$A=V]%`R37/:^KR>)/#2JKD"YE=F`R!B/OZ=:O\`B<L/"NK;%9F:
MTE4!1DDE2.*`*J>,=#<PD7I,<S!(Y_*?RF)Z#?C;G\:WR<"N3UNS6'X>164$
M)`$=M&L:+R/G3M74E2(2BG:VW`/IQ0!E#Q+IC7K6T<TLKI)Y+M'"[(K\?*6`
MQG\:U]JM@X!_"N0\(ZI8Z?HUGH]SNM=1B8QR0.ARSDY+#CD'.<UT\U[##>V]
MJY<2S[M@"DCCKDXP*`++(&4@]QBN9T9_LFKRVK\!LJ,]R.E=1VKF=>M'@N4O
MH<@$_-C^%AT-5#703(+I9='U?SD&48Y4=B#U%:G_``D%CY>\[]^/N;>:+:YM
M=:M!#.`)1U!ZY]14)\-0[N)Y-OICFJTVD+T*%N)=9U@2.N$7EAV4#H*FUR3[
M7J<-K'SMXX]36A/<6FC6AB@53*>BCDD^IJCH5J]Q=M>S?,`>">[>M._4#HHT
M"(%'8`4X(H.0HS]*=16104444`&!2!5'0#\J6B@#)UFROM0MC!9:@+-'!61A
M%O8J?[ISP??FKME9P:?8P6ENNV*&,1H/0`58P/04M`"%0>H!^M&!Z4M%`"%5
M/51^5+@>E%%`"!5!R%`/TI<444`)@>@HP/2EHH`0JIZ@?E4$EI!-<0W$D2-+
M#DQN1RN1@X].*L44`%%%%`!@>E&!Z444`)@>E+@444`)M7^Z./:EP/2BB@`I
MDL22Q-&Z@JPP0:?10!RE[H5Q;R&2US(F<X'#+58SZJ!Y>^Z],8/\\5V=%6J@
MN4Y6RT.XN9?,NMR1GJ"<LU=/%$D*)&BA548`%/%+4RES`D%%%%(84444`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
